People around the globe suffer from a myriad of rare diseases, many of which have no cure or limited treatment options. Many patients have been living without hope of a significant improvement in ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

The ability to make synthetic DNA and RNA by chemical or enzymatic means has revolutionized genetic research and drug discovery. Antisense technology employs short, chemically synthesized ...

- Ionis' novel antisense medicine targeting PCSK9 demonstrates best-in-class potential for the treatment of patients with high cholesterol at risk for cardiovascular disease CARLSBAD, Calif., Nov. 12, ...

For decades, antisense technology promised to transform the pharmaceutical industry. That moment has now arrived. Dr. Stanley Crooke, a pioneer in the field, explains what’s next. This article was ...

Regensburg, Germany, November 2, 2010 / b3c newswire / - The biopharmaceutical company Antisense Pharma announced today that their international, randomized and active-controlled Phase IIb study ...

Over the past decade, antisense technology has weathered many of the trials and tribulations facing any new branch of pharmacology, but it is now coming of age. One antisense drug, Isis ...

Ionis Pharmaceuticals has teamed up with Progenity to evaluate the oral systemic delivery of antisense oligonucleotides. The collaboration combines Progenity’s ingestible capsules with Ionis’ ...

With so many companies working on multiple approaches to interrupting messenger RNA and, hence, protein production, it comes as no surprise that the intellectual property (IP) surrounding antisense is ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Economic Moat Ionis has proprietary antisense oligonucleotide technology that has led to three approved RNA-based drugs and a steadily growing pipeline, which together support the firm's intangible ...